everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...6869707172737475767778...132133»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Afinitor (everolimus) / Novartis, paclitaxel / Generic mfg.
    [VIRTUAL] A preclinical model for skin sensitization prediction of antineoplasic drugs. () -  Apr 29, 2020 - Abstract #ASCO2020ASCO_3791;    
    Results obtained in this work suggest that pre-clinical assays may predict skin sensitization and be of potential value to predict skin sensitization of antineoplastic drugs before clinical development. Further assessment with in vivo tests will help to identify the cutaneous toxic mechanisms of those non-sensitizing drugs as cetuximab Research Funding: None
  • ||||||||||  Afinitor (everolimus) / Novartis, sirolimus / Generic mfg., sapanisertib (TAK-228) / Takeda
    [VIRTUAL] Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations. (Poster Board 373) -  Apr 29, 2020 - Abstract #ASCO2020ASCO_2460;    
    P2
    TAK228 is tolerable with differential activity in NFE2L2 (primary endpoint met) and KEAP1 mutant LUSC. A randomized phase 2 trial of TAK228 + docetaxel vs. SoC chemotherapy in advanced LUSC pts with NFE2L2/KEAP1 mut is in development (LungMAP S1900D) as is an NCI CTEP phase 1/1b trial of TAK228 + CB-839 in advanced NSCLC patients with NFE2L2/KEAP1 mut (NCI #10327).
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Enrollment closed, Trial primary completion date, Combination therapy, Metastases:  Palbociclib With Everolimus + Exemestane In BC (clinicaltrials.gov) -  Apr 28, 2020   
    P1b/2a,  N=41, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=1984 --> 1279 | Trial completion date: Jun 2031 --> Apr 2025 | Trial primary completion date: Jun 2021 --> Dec 2020 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2019 --> Jan 2021
  • ||||||||||  Afinitor (everolimus) / Novartis
    Continuation of mTOR Inhibition in LAM Patients Listed for Lung Transplant is Safe () -  Apr 26, 2020 - Abstract #ISHLT2020ISHLT_937;    
    Three were on sirolimus prior to listing; in two of those patients, sirolimus was switched to everolimus at time of listing...Conclusion While controversy abounds regarding the use of mTOR inhibitors during while listed for LTX in LAM patients, this case series suggest that continuation of mTOR inhibitor during waitlist phase before LTX is reasonable and safe. Programs should consider allowance of mTOR inhibition in LAM patients on the LTX waitlist.
  • ||||||||||  Afinitor (everolimus) / Novartis
    Survival in Lung Transplant Recipients on a Calcineurin Free Regimen: Is It Possible? () -  Apr 26, 2020 - Abstract #ISHLT2020ISHLT_769;    
    Methods An IRB-approved, retrospective, observational, cohort study of LTx recipients who received CNI-free, everolimus (EVR)-based immunosuppression at the University of Colorado from January 1, 1995 - October 1, 2019...Five of 12 were maintained on three agents (EVR, corticosteroid, and either methotrexate or azathioprine) and the others were on corticosteroids with EVR alone...Conclusion This review demonstrates that in certain situations withdrawal of CNI and transition to CNI-free, EVR- based immunosuppression may result in durable patient survival. Larger multicenter cohort analysis may be the next step in understanding the safety, efficacy and role of CNI-free immunosuppression, as equipoise would be impossible to achieve in a randomized controlled trial.
  • ||||||||||  Afinitor (everolimus) / Novartis, sirolimus / Generic mfg., University of Cincinnati
    Comparative Outcomes of Maintenance Immunosuppression Regimens in Heart Transplantation: Insights from Network Meta-Analysis () -  Apr 26, 2020 - Abstract #ISHLT2020ISHLT_279;    
    CNI+ mTA ranked better for CAV (p=0.78), CNI+AM for acute rejection (p=0.96) and mTA+AM for CMV infection (p=0.94) and improvement in renal function (p=0.86) than other regimens. Conclusion Different IS regimens have similar effects on survival post HT, but CNI+ mTA was associated with lower CAV rates, CNI+AM with less rejection, and mTA+AM with less CMV infection and improved eGFR post HT.
  • ||||||||||  tacrolimus / Generic mfg., Afinitor (everolimus) / Novartis
    The TEAMMATE Trial: Study Design and Rationale of the First Pediatric Heart Transplant Randomized Clinical Trial () -  Apr 26, 2020 - Abstract #ISHLT2020ISHLT_13;    
    In recent years, everolimus (EVL) has emerged as an alternative to tacrolimus (TAC) as a primary immunosuppressant to prevent rejection that may also prevent kidney and coronary disease...Methods The TEAMMATE Trial (IND 127980) is designed to evaluate the safety and efficacy of EVL and low-dose (LD-TAC) compared to standard-therapy TAC and mycophenolate mofetil (MMF)...Conclusion The TEAMMATE trial is the first RCT in pediatric HT. It is anticipated that the study will provide important information about the safety and effectiveness of EVL and TAC and provide valuable lessons into the design and conduct of future trials in pediatric HT.
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Upregulation of miR-101 during Influenza A Virus Infection Abrogates Viral Life Cycle by Targeting mTOR Pathway. (Pubmed Central) -  Apr 25, 2020   
    Moreover, treatment of the cells with Everolimus, a potent inhibitor of mTOR, resulted in an increase of miR-101 transcript levels, which further suppressed the viral protein synthesis. Collectively, the data suggest a novel mechanism that IAV stimulates mTOR pathway at early stages of infection; however, at a later time-point, positive regulation of miR-101 restrains the mTOR expression, and hence, the viral propagation.
  • ||||||||||  Afinitor (everolimus) / Novartis
    mTORC1 inhibition promotes human Treg differentiation via privileged mRNA translation  (Board Number: P803) -  Apr 25, 2020 - Abstract #IMMUNOLOGY2020IMMUNOLOGY_2313;    
    To answer this question, we performed genome-wide transcription and translation profiling in CD4+CD127dim/-CD25+ Tregs derived from anti-CD3/CD28-activated human naïve CD4+ T cells, treated with the mTORC1 inhibitor RAD001 and/or TGFβ...These canonical Treg fate-determining mRNAs were resistant to mTORC1 inhibition, an effect mediated in part by their 5’-untranslated regions through an alternate form of appears to be cap-dependent, eIF4E-independent mRNA translation. In conclusion, TGFβ transcriptional reprogramming together with mTORC1-independent translational reprogramming enable a privileged translation mechanism by which activated CD4+ T cells become Tregs.
  • ||||||||||  Afinitor (everolimus) / Novartis
    Journal:  New anti-epileptic drugs in Paediatrics (Pubmed Central) -  Apr 23, 2020   
    These new molecules have been developed in order to provide a pharmaceutical profile and tolerance superior to the previously available drugs, and it is forecast that as their use increases, their true potential and profile will widen. Furthermore, for the first time in Paediatric Epileptology, the extrapolation of the efficacy data in adults have been used (together with specific safety and pharmacokinetic studies in the paediatric population), in order to speed up their approval for use in the child population.
  • ||||||||||  Afinitor (everolimus) / Novartis
    Journal:  Preparation and study of two kinds of ophthalmic nano-preparations of everolimus. (Pubmed Central) -  Apr 22, 2020   
    Micelles could be achieved in the eye and maintained for a long time. The preparation of everolimus micelles or nanosuspension for eye are suitable for ocular administration and expected to be new dosage form for corneal transplantation immunological rejection or other ocular disease.
  • ||||||||||  Afinitor (everolimus) / Novartis
    Clinical, Review, Journal, PD(L)-1 Biomarker, IO Biomarker:  mTOR Links Tumor Immunity and Bone Metabolism: What are the Clinical Implications? (Pubmed Central) -  Apr 22, 2020   
    Furthermore, inhibitors of mammalian target of rapamycin are demonstrated to actively modulate osteoclastogenesis, exert antiapoptotic and pro-differentiative activities in osteoclasts, and reduce the number of lytic bone metastases, increasing bone mass in tumor-bearing mice. With regard to the many actions in which mTOR is involved, the aim of this review is to describe its role in the immune system and bone metabolism in an attempt to identify the best strategy for therapeutic opportunities in the metastatic phase of solid tumors.